PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Actelion Pharmaceuticals Ltd.

USPTO PatentsView assignee record - 73 granted patents across 9 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company
Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Actelion ranks #4,749 of 49,997 tracked US assignees by granted-patent volume, with 73 patents across 9 technology areas.

#4,749
of 49,997 US assignees by volume
Top 35%
by Innovation Score (40.6/100)
16.1
avg claims per patent
-71%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R4749 · Foreign Corporation #4,749 · 73 grants

GRANTS-SMALL · TOP-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

  • GRANTS-SMALL 73 grants
  • TOP-DECILE #4,749/49,997
  • PHOTO-FINISH Aware
  • CPC-NARROW A61P · 9 areas
  • INNOV-PAR 40.6/100
  • CLAIMS-RICH 16.1 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-DROP -71% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Aware, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Actelion

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Actelion's Innovation Score is 40.6/100 (top 35% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Actelion's grants concentrate

Actelion Pharmaceuticals Ltd. is a focused PatentsView assignee: 9 CPC subclasses with 87.7% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2016 (21 grants) versus a trough of 1 in 2018. By volume, Actelion sits between Wuhan Xinxin Semiconductor Manufacturing Co., Ltd. and C. & E. Fein GMBH.

Actelion's three-year grant acceleration

Actelion Pharmaceuticals Ltd. shows 9 grants in 2022–2024 against only 11 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Actelion's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Actelion holds 73 patents at rank #4,750, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Actelion

By rank, the assignees closest to #4,750 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Actelion's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Actelion, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (41 here).

Io Therapeutics, Inc 41 Kyowa Kirin Co., Ltd. 41 Mbda Deutschland GmbH 41 K4connect Inc. 41

Similar claim depth

Nearest assignees by average claims per patent (16.1 here).

GLO AB 16.1 avg Bracco Imaging S.P.A. 16.1 avg Faurecia Systemes D'echappement 16.1 avg Vitesco Technologies USA, LLC 16.1 avg

Actelion's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

41 Top 35% higher than 65% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0510152025 20152016201720182019202020212022202320242025 1
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Actelion Pharmaceuticals Ltd. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 17 23.3%
2016 21 28.8%
2017 13 17.8%
2018 1 1.4%
2019 4 5.5%
2020 4 5.5%
2021 3 4.1%
2022 2 2.7%
2023 6 8.2%
2024 1 1.4%
2025partial year 1 1.4%

Which technologies does Actelion Pharmaceuticals Ltd. patent most?

Top 9 of 9 technology areas

Where it ranks

Overall rank by patents

#4,749

of 49,997 tracked assignees

Innovation Score

40.6 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Actelion Pharmaceuticals Ltd.'s patent record in context - here's where to go next.

  • Actelion Pharmaceuticals Ltd.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 87.7% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #4,749 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Actelion Pharmaceuticals Ltd. against Wuhan Xinxin Semiconductor Manufacturing Co., Ltd., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 40.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.